Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248
Terminated
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2018
Locations: Not set, Christiansburg, Virginia +2 locations
Conditions: Multiple Myeloma
Register for Updates
Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)
NCT01238536
Completed
The broad, long-term objective of this research protocol is to improve the quality of life for patients suffering from lumbar spinal stenosis. This objective will be met by examining the safety and clinical efficacy of epidural steroid injections for treatment of pain associated with lumbar spinal stenosis. This prospective, randomized, double-blind controlled trial (RCT) will test the hypothesis that the effectiveness of epidural steroid injections (ESI) plus local anesthetic (LA) is greater th... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
11/15/2017
Locations: Virginia Spine Research Institute, Richmond, Virginia
Conditions: Spinal Stenosis, Low Back Pain
Register for Updates
Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
NCT01994642
Terminated
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis media in children with patent tympanostomy tubes.
Gender:
ALL
Ages:
Between 6 months and 12 years
Trial Updated:
09/22/2017
Locations: The Education and Research Foundation, Inc, Lynchburg, Virginia
Conditions: Otitis Media in Patients With Tympanostomy Tubes
Register for Updates
A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
NCT01980589
Completed
The primary objective was to determine the maximum tolerated dose of carfilzomib given twice weekly in combination with cyclophosphamide and dexamethasone for patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2017
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Multiple Myeloma
Register for Updates
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
NCT01056276
Completed
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2017
Locations: Peninsula Cancer Institute, Newport News, Virginia
Conditions: Multiple Myeloma
Register for Updates
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259
Completed
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more ef... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/15/2017
Locations: University of Virginia Cancer Center, Charlottesville, Virginia +5 locations
Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
NCT00097981
Completed
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: Not set, Fairfax, Virginia +2 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
NCT00096135
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.
Gender:
ALL
Ages:
Between 18 months and 29 years
Trial Updated:
02/14/2017
Locations: Inova Fairfax Hospital, Falls Church, Virginia +1 locations
Conditions: Leukemia
Register for Updates
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
NCT00343460
Completed
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/10/2017
Locations: Cancer Outreach Associates - Abingdon, Abingdon, Virginia +1 locations
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
NCT02069093
Completed
Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/20/2016
Locations: Delta Oncology Associates Delta Hematology/Oncology, Portsmouth, Virginia
Conditions: Advanced Breast Cancer
Register for Updates
A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
NCT01910155
Terminated
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par Pharmaceutical Companies, Inc.) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis externa.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2016
Locations: The Education and Research Foundation Inc., Lynchburg, Virginia
Conditions: Otitis Externa
Register for Updates
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
NCT01188187
Completed
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line docetaxel/prednisone treatment alone. This will be a randomized, open-label, multicenter, international trial. Treatment will consist of docetaxel/prednisone/custirsen vs. docetaxel/prednisone. A total of at least 1000 patients will be randomized. Patients will be randomly assigned with... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/13/2016
Locations: Teva Investigational Site 047, Newport, Virginia +1 locations
Conditions: Prostate Cancer
Register for Updates